Hepatitis/MASH

Researchers determine how the liver is able to naturally inhibit HCV infection.

Scientists discover threat from AAV2 virus and from correlation to the development of liver cancer.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.

Likelihood of co-infection linked closely to intravenous drug use more often than risky sexual activities in patients with HIV and hepatitis C.

Pollutants may accelerate fibrosis, metabolic disease, and liver cancer.

NS3 enzyme interacts with RNA and helps the pathogen replication process.

Psychosis and hepatic fibrosis associated with earlier mortality.

Legislators focus on the pricing of sofosbuvir and Harvoni.

Johnson & Johnson has announced the completion of the acquisition of Novira Therapeutics, a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus infection.

The World Health Organization indicates that 35 million individuals have HIV worldwide, and 4 to 5 million HIV-infected patients are co-infected with hepatitis C virus.

FDA decision expected in second half of 2016.

Study finds potential link between HCV treatment and drug-induced hepatotoxicity.

Hepatitis C infection causes more deaths than HIV, hepatitis B, and tuberculosis combined.

A new study shows that adding a third drug to the ingredients in Harvoni could cure hepatitis C in half the ordinary time.

In California, a class action lawsuit has been filed on behalf of thousands of Blue Cross beneficiaries living with hepatitis C who were denied treatment.

One-step test will screen, detect and confirm a hepatitis C virus infection.

Near-fatal car accident leads man down long journey from infection to cure for hepatitis C.

Some of the basic research behind NS5B inhibitors reveals an often overlooked, but clinically important difference between Viekira Pak and Harvoni.

Extrahepatic manifestations may be important clues in the diagnosis of hepatitis C infection.

Effective therapies in liver transplant patients reduces HCV recurrence.

Patients on Medicaid more likely to have HCV infection and much more likely to be denied coverage.

Number of infected people is projected to drop below 1 million by 2020, but with substantial HCV disease and death burden.

Antiretroviral drug interactions now included due to high prevalence of HIV coinfection among patients with hepatitis C virus.

How treatment with Harvoni changed the life of a patient infected with HCV.